Development

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Articles

Many antibody-drug conjugate therapies are in the pipeline; only a handful have been approved. What are the bottlenecks?

Formulating an ADC Development Solution

Inovio received a $71-million contract from the US Department of Defense to scale up manufacture of its Cellectra smart device to deliver its DNA vaccine.

Inovio to Scale-Up Manufacture of Intradermal Delivery Device for its COVID-19 Vaccine

Intertek has announced the expansion of its pharmaceutical services laboratory in Melbourn, near Cambridge, UK, through the acquisition of a new 20,000 sq. ft facility.


Intertek Expands Pharma Services Facility

The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization approval for AstraZeneca’s benralizumab, a monoclonal antibody for treating severe asthma.

AstraZeneca Gets Positive EMA Opinion on Respiratory Biologic

The authors of the study believe it could have significant implications for the discovery of new dermatological products for major diseases such as psoriasis.

New Study Challenges Current Theories on Skin Delivery of Macromolecules

Through the support of the Japanese agency, Daiichi Sankyo intends to further develop its genetic vaccine platform focused around its new nucleic acid delivery technology. 

Japanese Agency Supports Daiichi Sankyo’s Genetic Vaccine Platform

Adeline Siew is science editor for BioPharm International.

There is a lot of interest in delivering biologics via non-invasive routes in attempt to improve patient compliance and convenience. 


Formulation of Biologics for Non-Invasive Delivery

Lonza further expands its micronization services with the acquisition of Swiss contract manufacturer, Micro-Macinazione, following its previous $5.5-billion acquisition of dosage form provider, Capsugel.

Lonza Boosts Micronization Capacity with Acquisition

Randi Hernandez was science editor at BioPharm International from September 2014 to May 2017.

Amgen discussed the drug-delivery approaches to two of its biologics in a recent second-quarter earnings call.

Amgen: Neulasta Safe for Now; Dose Accuracy of Erenumab a New Focus

The wearable devices for the delivery of biologic products are now being manufactured and will be tested in clinical trials in the near future, according to the company.

Formulation and Drug Delivery, Specialty Dosage Forms